KRAS P.G12C Clinical Trials in Fuzhou, Fujian
2 recruitingFuzhou, Fujian, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205